30-Month Stay: How Litigation Delays Generic Drug Approval
The 30-month stay under the Hatch-Waxman Act is a legal tool that delays generic drug approval when patent lawsuits are filed. It's meant to protect innovation, but often extends monopolies, hikes drug prices, and leaves patients waiting years for affordable alternatives.
Read More